Kyowa Kirin, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1949-01-01
- Employees
- 7.1K
- Market Cap
- $12B
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00456586
- Locations
- ๐บ๐ธ
Contact Kyowa Pharmacuetical Inc., Princeton, New Jersey, United States
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00346632
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
๐บ๐ธContact Kyowa, Princeton, New Jersey, United States
๐บ๐ธM.D. Anderson Cancer Center, Houston, Texas, United States
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00199446
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 1100
- Registration Number
- NCT00199368
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT00199407
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT00199381
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00199342
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center- University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 580
- Registration Number
- NCT00199420
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
๐บ๐ธKyowa Pharmaceutical, Princeton, New Jersey, United States
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00199433
- Locations
- ๐บ๐ธ
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States